Michael Weitzendorfer

Dr. Michael Weitzendorfer

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2019 in The Laryngoscope
Verified
Journal Article
Open access
PDF file
MWMichael Weitzendorfer
Michael Weitzendorfer
SAStavros A. Antoniou
Stavros A. Antoniou
PSPhilipp Schredl
Philipp Schredl
KWKai Witzel
Kai Witzel
IWIsabella C. Weitzendorfer
Isabella C. Weitzendorfer
OKOliver O. Koch
Oliver O. Koch
Objectives: The aim of this study was to compare the diagnostic accuracy of salivary pepsin with oropharyngeal pH monitoring using the Restech measurement system (Dx‐pH) for the diagnosis of laryngopharyngeal reflux (LPR).Study Design: Prospective cohort study.Methods: Seventy patients with primary symptoms related to LPR underwent gastroscopy, high‐resolution manometry, pH throughout 24‐hour monitoring (MII‐pH), and barium esophagography between October 2015 and May 2018. In addition, an ear, nose, and throat examination was performed, including assessment of Belafsky Reflux Finding Score (RFS). Clinical symptoms were evaluated with the Belafsky Reflux Symptom Index (RSI) and the Gastrointestinal Quality of Life Index (GIQLI). Simultaneous to MII‐pH, pepsin determination and Dx‐pH were performed.Results: Of 70 patients, 41 (58.6%) subjects with a pathological DeMeester score showed higher mean values of pepsin (mean value: 216 ng/mL, 95% confidence interval [CI]: 172 to 260), compared to patients with a normal DeMeester score (mean value: 161 ng/mL, 95% CI: 115 to 207). Salivary pepsin showed a specificity of 86.2% and sensitivity of 41.5% for diagnosing LPR using the optimal cutoff value of 216 ng/mL. Furthermore, a significant correlation between the values of salivary pepsin and the RSI score was seen in patients with pathological results in MII‐pH (r = 0.344; P = 0.046).However, elevated Dx‐pH measurements showed no significant correlation with either MII‐pH, RSI score, RFS score, or GIQLI score, or with the results of pepsin measurement.Conclusion: Pepsin measurement in saliva could be an alternative tool to assist office‐based diagnosis of LPR, whereas Dx‐pH does not seem to be an adequate test.Level of Evidence: 2B Laryngoscope, 130:1780–1786, 2020

19 September 2017 in European Surgery
Verified
Journal Article
Open access
PDF file
MWMichael Weitzendorfer
Michael Weitzendorfer
GKGernot Köhler
Gernot Köhler
SAStavros A. Antoniou
Stavros A. Antoniou
LPLeo Pallwein-Prettner
Leo Pallwein-Prettner
LMLisa Manzenreiter
Lisa Manzenreiter
OKOliver Owen Koch
Oliver Owen Koch
The assessment of hiatal hernias (HH) is typically done with barium swallow X‑ray, upper endoscopy, and by high-resolution esophageal manometry (HRM). The aim of this study was to assess the clinical utility of these methods in terms of HH detection and their correlation to gastroesophageal reflux disease (GERD).

30 March 2018 in Surgical Endoscopy
Verified
Journal Article
Open access
PDF file
MWMichael Weitzendorfer
Michael Weitzendorfer
GSGeorg O. Spaun
Georg O. Spaun
SAStavros A. Antoniou
Stavros A. Antoniou
KWKai Witzel
Kai Witzel
KEKlaus Emmanuel
Klaus Emmanuel
OKOliver O. Koch
Oliver O. Koch
Background: Previous studies suggest clinical effectiveness of endoscopic full-thickness plication in selected patients with gastroesophageal reflux disease (GERD). The aim of this study was to assess the clinical safety and efficiency of the GERDx™ device by evaluating clinical parameters, reflux symptom scores, and quality of life (QoL). Methods: Prospective one-arm trial evaluating the outcome of forty patients with GERD subjected to endoscopic plication with the GERDx™ device. We included patients with at least one typical reflux symptom despite treatment with a PPI for > 6 months, pathologic esophageal acid exposure, hiatal hernia of size < 2 cm, and endoscopic Hill grade II–III. Evaluation of Gastrointestinal Quality of Life Index (GIQLI), symptom scores, esophageal manometry, and impedance-pH-monitoring were performed at baseline and at 3 months after surgery. (Trial Registration: ClinicalTrials.gov NCT 01798212.) Results: There were no intraoperative complications. Four out of forty patients experienced postoperative complications requiring intervention. Seven of forty patients were subjected to laparoscopic fundoplication 3 months after endoscopic plication due to persistent symptoms and were lost to further follow-up. Thirty out of forty patients were available at 3-month follow-up. There was an improvement of the GIQLI score, from a mean of 92.45 ± 18.47 to 112.03 ± 13.11 (p < 0.001). The general reflux-specific score increased from a mean of 49.84 ± 24.83 to 23.93 ± 15.63 (p < 0.001), and the DeMeester score from a mean of 46.48 ± 30.83 to 20.03 ± 23.62 (p < 0.001). There was no significant change in manometric data after intervention. Three of thirty patients continued daily antireflux medication. Conclusions: Endoscopic plication with the GERDx™ device reduced distal acid exposure of the esophagus, reflux-related symptoms, and improved GIQLI scores with minimal side effects in a selected cohort of patients and may be a safe alternative in the treatment of GERD.

1 May 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
Patrick KirchwegerPatrick Kirchweger
Patrick Kirchweger
AKAlexander Kupferthaler
Alexander Kupferthaler
JBJonathan Burghofer
Jonathan Burghofer
GWGerald Webersinke
Gerald Webersinke
EJEmina Jukic
Emina Jukic
HWHelwig Wundsam
Helwig Wundsam

1 November 2021 in Surgery
Verified
Journal Article
Closed access
MSMoritz B. Sparn
Moritz B. Sparn
BWBernhard Widmann
Bernhard Widmann
UPUrs Pietsch
Urs Pietsch
MWMichael Weitzendorfer
Michael Weitzendorfer
RWRene Warschkow
Rene Warschkow
TSThomas Steffen
Thomas Steffen

26 April 2024 in Diseases of the Esophagus
Verified
Journal Article
Open access
PDF file
MVMaurits Rijndert Visser
Maurits Rijndert Visser
DVDaan M Voeten
Daan M Voeten
SGSuzanne S. Gisbertz
Suzanne S. Gisbertz
JRJelle Ruurda
Jelle Ruurda
MAMichael Patrick Achiam
Michael Patrick Achiam
RHRichard van Hillegersberg
Richard van Hillegersberg
Reasons for structural and outcome differences in esophageal cancer surgery in Western Europe remain unclear. This questionnaire study aimed to identify differences in the organization of esophageal cancer surgical care in Western Europe. A cross-sectional international questionnaire study was conducted among upper gastrointestinal (GI) surgeons from Western Europe. One surgeon per country was selected based on scientific output and active membership in the European Society for Diseases of the Esophagus or (inter)national upper GI committee. The questionnaire consisted of 51 structured questions on the structural organization of esophageal cancer surgery, surgical training, and clinical audit processes. Between October 2021 and October 2022, 16 surgeons from 16 European countries participated in this study. In 5 countries (31%), a volume threshold was present ranging from 10 to 26 annual esophagectomies, in 7 (44%) care was centralized in designated centers, and in 4 (25%) no centralizing regulations were present. The number of centers performing esophageal cancer surgery per country differed from 4 to 400, representing 0.5–4.9 centers per million inhabitants. In 4 countries (25%), esophageal cancer surgery was part of general surgical training and 8 (50%) reported the availability of upper GI surgery fellowships. A national audit for upper GI surgery was present in 8 (50%) countries. If available, all countries use the audit to monitor the quality of care. Substantial differences exist in the organization and centralization of esophageal cancer surgical care in Western Europe. The exchange of experience in the organizational aspects of care could further improve the results of esophageal cancer surgical care in Europe.